Resomelagon

Resomelagon

SCHEMBL30065234

NC(N)=N/N=C\C=C/c1cccn1-c1ccccc1[N+](=O)[O-]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.45
▸ GRIN2D O15399 6/20 0.45
▸ GRIN3B O60391 6/20 0.45
▸ GRIN1 Q05586 6/20 0.45
▸ GRIN2A Q12879 6/20 0.45
▸ GRIN2B Q13224 6/20 0.45
▸ GRIN2C Q14957 6/20 0.45
▸ GRIN3A Q8TCU5 6/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MAPT P10636 5/20 0.40
▸ PLAU P00749 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ GAA P10253 4/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ F2 P00734 1/20 0.36
▸ PRSS1 P07477 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Resomelagon SCHEMBL29214574 1.00 KMT2A (0.45) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
Resomelagon SCHEMBL30064288 1.00 KMT2A (0.45) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
Resomelagon SCHEMBL12123977 1.00 KMT2A (0.45) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
Resomelagon SCHEMBL29214576 1.00 KMT2A (0.45) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
Resomelagon SCHEMBL29214577 1.00 KMT2A (0.45) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
Resomelagon SCHEMBL30064248 0.94 KMT2A (0.44) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
Resomelagon SCHEMBL31670337 0.94 KMT2A (0.44) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
Resomelagon SCHEMBL31670336 0.93 GRIN2D (0.41) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL26038037 0.91 KMT2A (0.46) KMT2AGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL12657546 0.86 GRIN2D (0.39) KMT2AGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12239631-B2 Polymorphs of phenyl pyrrole aminoguandium salts SYNACT PHARMA APS (DK) 2025-03-04 — — US disclosed
US-20240335423-A1 POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS SYNACT PHARMA APS (DK) 2024-10-10 — — US disclosed
EP-4359383-A1 SALTS OF PHENYL PYRROLE AMINOGUANIDINE AND POLYMORPHS OF PHENYL PYRROLE AMINOGUANIDINIUM SALTS SynAct Pharma ApS (DK) 2024-05-01 — — EP disclosed
US-20230271922-A9 POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS SYNACT PHARMA APS (DK) 2023-08-31 — — US disclosed
US-20230002319-A1 POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS SYNACT PHARMA APS (DK) 2023-01-05 — — US disclosed
WO-2022268814-A1 SALTS OF PHENYL PYRROLE AMINOGUANIDINE AND POLYMORPHS OF PHENYL PYRROLE AMINOGUANIDINIUM SALTS SYNACT PHARMA APS (DK) 2022-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271922-A9 POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS HLA-C, HLA-DRB1, HLA-B KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885
US-12239631-B2 Polymorphs of phenyl pyrrole aminoguandium salts HLA-C, HLA-DRB1, HLA-B KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885
US-20230002319-A1 POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS HLA-C, HLA-DRB1, HLA-B KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885
US-20240335423-A1 POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS HLA-C, HLA-DRB1, HLA-B KMT2A 4584/4885GRIN2D 2363/4885GRIN3B 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback